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The objective of the article was to describe a patient with amyotrophic lateral sclerosis (ALS) 
treated with nutraceuticals who had a better quality of life and improved muscle strength. A 
65-year-old male patient with a past medical history of gout was diagnosed with amyotrophic 
lateral sclerosis in 2016. He received intravenous immunoglobulin and prednisone, but no 
improvement was observed. In 2018, he was diagnosed with multiple myeloma, submitted 
to a bone marrow transplant, and initiated riluzole. After 2 months, he came to our private 
clinic; he could not walk anymore and used outpatient nasal ventilator equipment. Beck anxi-
ety inventory (BAI) was 20 [normal range (nr): <  8], Beck depression inventory (BDI) was 
12 (nr: <  10), Bristol stool form scale (BSTS) was 5 (nr: 3–4), and there were 7 symptoms of 
dysbiosis. Analogic visual scale (Lickert scale) for well-being was 5.0. We suspended the col-
chicine, added vitamin D3, creatine, vitamin C, N-acetyl cysteine, 5-hydroxytryptamine, B1, 
and B6 vitamins. Dysbiosis was also treated. After 2 months, he returned feeling much better, 
BAI and BDI reduced BDI to 11, and BSFS normalized. Following this evaluation, a nutra-
ceutical prescription was added: methylfolate, zinc, magnesium, green tea extract, Ginkgo 
biloba, lipoic acid, pyrroloquinoline quinone, vitamin E, coenzyme Q10, and resveratrol. Af-
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ter 7 months, he was feeling very well; BAI and BDI were normal, he gained weight. He felt a 
marked improvement in his muscle strength, and he gained again the capacity of eating alone, 
his quality of life improved, and AVS well-being was 8.0. This report illustrates a demonstra-
tive case of a patient with ALS treated with nutraceuticals and improved his quality of life and 
muscle strength. It may be an alternative therapeutic option for such patients.
Keywords: amyotrophic lateral sclerosis, neurological disorders, lower neuron disease, immu-
nity, vitamin D, nutraceuticals, supplements.
Introduction
Amyotrophic lateral sclerosis (ALS) is the prototype motor neuron disease with the 
presence of degeneration of the anterior horn of the spinal cord, motor nuclei of the cra-
nial nerves, and pyramidal cells in the motor cortex. The aetiology of ALS is unknown, 
although the trigger roles of repeated cranial traumas, certain infections and monoclonal 
gammapathies are suggested. The pathogenesis includes autoimmune links, which hy-
pothesis is supported by the association of ALS with other autoimmunopathies and with 
higher prevalence of certain HLA haplotypes in it. Autoantibodies from ALS patients sera 
may induce apoptotic death of motor neurons in cell culture and anterior horn damage 
by passive transfer to mice. Autoantibodies against voltage-dependent calcium channels 
and few other targets (neurofilaments, Fas receptor (CD95), fetal muscular proteins, and 
vascular antigens) are blamed for that. Also, T-cell/macrophareal infiltration of spinal an-
terior horns has been registered in cases of ALS. The targeted neurons undergo degenera-
tion under influence of immune and other complex mechanisms, increase of intracellular 
calcium ions’ concentration, glial activation and M1-polarization, reactive oxygen species 
hyperproduction, glutamate excitotoxicity, protein misfolding with ubiquitinated aggre-
gates and disorder of proteasome functions [1–3]. This degeneration causes progressive 
palsy of skeletal muscles leading to a paresis of lower and upper limbs. During the pro-
gression of the illness, intercostal, phrenic and esophageal muscles may also be involved, 
due to involvement of medulla oblongata, with respiratory insufficiency and dysphagia, 
resulting in weight loss and malnutrition [1]. The median time of survival after the onset 
of ALS symptoms is 32 months [4].
There is no definitive treatment for ALS. The only therapeutical agent available is rilu-
zole, a noncompetitive metabolotropic glutamate receptor 1 (mGluR1) antagonist, which 
may prolong survival by only 2 to 3 months [5].
New modalities of treatment are therefore desired. In this line, low-risk treatments to 
improve life quality, prolong survival, and reduce comorbidities are extremely desired in 
this neurological disorder. Using a holistic approach with complementary and alternative 
medicine may be an additional option for such patients to improve their quality of life and 
some aspects of muscle strength.
The purpose of this article is to report the case of a patient with ALS who was treated 
using a combination of nutraceuticals and had a better quality of life and muscle strength. 
Case report 
A 65-year-old male patient with a past medical history of gout for 20 years; started 
to feel in December 2016 progressive mild muscle weakness in his hands, and then he 
noted the difficulty of cut foods and bring them to his mouth, later he felt the difficulty 
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of use stairs, and the symptoms progressed. His cerebrospinal fluid was normal. Elec-
troneuromyography showed alteration of the anterior horn of the spinal cord on cervical 
and lumbar regions of the spine. He was diagnosed with amyotrophic lateral sclerosis by 
the neurologist. He had positive serological data for Lyme disease and received antibiot-
ics (ceftriaxone 2 g/day) for 30 days but without any improvement. In January 2018, he 
received human polyclonal intravenous immunoglobulin G, but no change was noted. 
He also was treated with prednisone 80 mg/day for 8 months with progressive tapering, 
but no improvement was observed. In July 2018, he was diagnosed with multiple my-
eloma, and in August 2018, he was submitted to a bone marrow transplant and developed 
pulmonary thromboembolism in the post-operative transplant. Riluzole 50 mg twice a 
day was initiated to him. After 2  months, he came to our private clinic. He could not 
walk anymore. His physical examination demonstrated a pale patient using a nasal bi-
level positive airway pressure (BIPAP) in an outpatient ventilator equipment. His weight 
was 64 kg and height 1.68 m, and body mass index (BMI) 22.7 kg/m2. He had atrophy of 
hand interosseous muscles and several muscle atrophies of his forearm and thigh mus-
cle groups. Furthermore, the spasticity of lower limbs was noted on passive flexion and 
extension. His muscle strength was grade 3/5 in upper limbs and 2/5 in lower limbs; the 
legs were paretics. All reflexes were exacerbated, and fasciculations were observed in arms 
and legs. Blood pressure was 110 × 80 mm Hg, heart rate of 64 bpm, Cardiovascular, lung, 
and abdomen examination was unmarked. Beck anxiety inventory (BAI) was 20 [normal 
range (nr): < 8], Beck depression inventory (BDI) was 12 (nr: < 10), Pittsburgh sleep scale 
was 3 (nr: < 7), Bristol stool form scale (BSTS) was 5 (nr: 3–4), and there were 7 symp-
toms associated with dysbiosis. Analogic visual scale (Lickert scale) for well-being was 
5.0 (reference: 0, worst, and 10, best). He was under methylcobalamin 50 mg subcutane-
ously twice a week, colchicine 1mg/day, riluzole 100 mg/day, and tauroursodeoxycholic 
acid 250 mg/day. Laboratory tests revealed hemoglobin 12.3 g/dL (nr: 13–18 g/dL), white 
blood cell 3,260 cells/mm3 (nr: 4,000–10,000 cells/mm3), eosinophils were 690 cells/mm3 
(nr; < 500 cells/mm3), platelets 208,000 cells mm3, creatine kinase of 1.050 U/L (nr: 32–
294  U/L), vitamin D3  28.3  ng/mL [normal range (nr): > 30 ng/mL], albumin 39.7  g/L 
(nr; 35–47 g/L), AST 34 (nr: < 35 U/L0, ALT 23 U/L (nr: < 30 U/L) and homocysteine 
10.3 mmol/L (optimal range: < 8 mmol/L). Antinuclear antibodies, anti-dsDNA, anti-Sm, 
anti-Ro/SS-A, anti-La/SS-B, anti-U1RNP, anti-mitochondria, anti-thyroglobulin, anti-
thyroperoxidase, and anti-CCP were all absent. Immunoglobulin levels were within the 
normal range. Magnetic resonance imaging of the brain and spinal cord gave normal im-
ages. Polysomnography revealed an index of apnea-orthopnea mildly increased and the 
presence of 34 episodes of desaturation. Serological data for infectious diseases, such as 
HIV 1 and 2, syphilis, rubella, mononucleosis, hepatitis B and C virus, cytomegalovirus, 
herpes type  1 and 2, toxoplasmosis  — were all negative. We suspended the colchicine 
since this drug may induce or worse myopathy; we added vitamin D3 10.000I U/day, cre-
atine 5 g/day, vitamin C 500 mg/day, N-acetyl cysteine 400 mg/day, 5-hydroxytryptamine 
300 mg/day, thiamine 100 mg/day, and pyridoxine 100 mg/day. For dysbiosis, were pre-
scribed albendazole 400 mg once and an additional dose after 15 days; glutamine 5 g twice 
a day, quercetin 250 mg/day, and vitamin A 25.000 Iu/day for 2 months. A gluten-free diet 
was suggested, removing all foods with wheat, rye and barley. After 2 months, he returned 
feeling much better, and vitamin D increased to 48.3  ng/mL, CK reduced to 484  U/L, 
eosinophils normalized to 243 cells/mm3, an increase in weight was seen, BAI reduced to 
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16, and BDI to 11, and BSFS normalized in 3. Following this evaluation, this nutraceutical 
prescription was added: vitamin D3 was increased to 20.000 IU/day, methylfolate 1 mg, 
zinc 30 mg, iodine 500 mcg, magnesium 200 mg, green tea extract 300 mg, Ginkgo bi-
loba 100 mg, lipoic acid 600 mg, pyrroloquinoline quinone 20 mg, and vitamin E 400 IU 
once a day. Coenzyme Q10 200 mg plus resveratrol 50 mg was administered transdermally 
once a day. D-ribose 5 g once a day. And he continues using riluzole associated with the 
nutraceuticals. After 7 months, he felt very well; BAI was 8, BDI was 9, he gained weight 
and stayed with 72.5 kg, with a BMI of 25.5 kg/m2, and his muscle strength was grade 4/5 
in upper limbs and 3/5 in lower limbs; although the legs continued were paretics No evi-
dence of myeloma multiple was seen as evidenced by the normal calcium, creatinine, total 
protein and serum albumin concentration. He felt a marked improvement in his muscle 
strength, and he gained again the capacity of eating alone, his quality of life improved, and 
AVS was 8.0. 
Discussion
This article reports a patient who suffered from ALS and experienced improved mus-
cle strength and quality of life when treated with a combination of some nutraceuticals 
and a gluten-free diet.
From the point of view of pathology, the co-morbidity of this ALS case with multiple 
myeloma is remarkable. The association of these entities was noticed before, with either 
ALS (or related motor neuron disorders) diagnosis established prior to myeloma, or vice 
versa monoclonal gammapathies, including myeloma or other lymphomas, debuted be-
fore ALS elicited [6–10]. Concerning Lyme disease, it was probably a false positive serol-
ogy, since the adequate treatment with ceftriaxone 2 g/day for 30 days did not change the 
clinical picture of the patient. 
A blend of strategies was used in our patient. Indeed, we supplemented him with 
vitamin D since the serum levels of vitamin D were low, and, also, there is evidence in the 
literature about its deficiency in ALS as well as its protective role in autoimmune diseases 
[11; 12]. More so, significantly, low vitamin D is associated with more ALS severity [11]. 
The use of vitamin D supplementation in ALS was already studied. Its efficacy was sup-
ported by a study with 34 ALS subjects supplemented with 2,000 IU/day and improved 
functionality in these patients [13]. 
Concerning creatine supplementation, a study that reported using this derivative of 
amino acids in 28  patients with a dosage of 20  g/day for 7  days and then 3  g/day for 
3–6 months showed an increase of maximal isometric power these patients [14].
Regarding vitamin C and E, an extensive prospective study of ALS prevention evalu-
ated 957,740 healthy individuals, who regularly used vitamins E and C and was followed 
from 1989 to 1998, and the authors observed 525 deaths from ALS. Interestingly, regular 
use of vitamin E supplements was associated with a lower risk of dying of ALS. However, 
no significant associations were found for the use of vitamin C or multivitamins [15].
Hyperhomocysteinemia is frequently found in patients with ALS. A study that evalu-
ated 62 patients with ALS and 88 age- and sex-matched controls verified a higher median 
plasma homocysteine levels (11.2  vs. 9.7  micromol/L, p = 0.0004)  lower folate levels in 
patients compared to controls. Moreover, multivariate logistic regression revealed a robust 
direct association between plasma homocysteine levels and ALS presence and a shorter 
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interval onset ALS diagnosis [16]. A high dose of methylcobalamin, a methylating agent, 
was tested in ALS, showing a prolonged survival and retarding symptomatic progression 
without significant side effects if started early in these patients [17].
5-hydroxytryptamine was offered to the patient to improve anxiety and depression 
symptoms, and this good result was observed in our case. In fact, in a Cochrane review, 
5-HTP had a good effect on depressive patients than controls [18]. 
A scheme for dysbiosis was used in the patient, with albendazole, to kill pathogenic 
intestinal parasites. In ALS patients, few case reports exist of ALS associated with the 
presence of parasites such as schistosomiasis, babesiasis, and borrelia. Moreover, the ALS 
clinical manifestations improved after treatment with ceftriaxone and anti-babesia ther-
apy [19; 20]. 
Quercetin as well as plantar polyphenols, bioflavonoids and resveratrol are able to 
render therapeutic effect in ubiquitinization/proteasome function disorders of ALS and 
similar diseases, as it was shown recently by comprehensive meta-analysis [3]. Also 
quercetin and vitamin A has an essential role in the intestinal epithelization process, con-
tributing to dysbiosis improvement [21; 22].
Pyridoxine and thiamine supplementations were implemented in our patients to im-
prove anxiety and depression symptoms. A study could show that there was a 28 % thia-
mine deficiency in ALS patients [23]. Another study showed the effectiveness of a high 
dose of pyridoxine for anti-stress activity [24]. Moreover, the association of magnesium 
200 mg and pyridoxine 50 m may reduce anxiety symptoms [25]. Our patient received 
both elements and had a marked reduction of anxiety. 
Zinc levels are inversely associated with the presence of ALS and also with ALS pa-
tients’ function impairment [26]. Lipoic acid supplementation was reported in a similar 
case report with a good outcome [27]. However, this substance was administered together 
with other treatments, as in our patient. An experimental study has shown a good effect of 
Ginkgo biloba in mice with ALS [28]. 
Concerning coenzyme Q10, it is commonly used in various degenerative neurologi-
cal diseases, including ALS. An exciting review of coenzyme Q10 in these neurological 
conditions is available (see reference 21) [29].
Future randomized and controlled studies with the combined use of several nutra-
ceuticals as complementary therapeutics for ALS are desired to confirm our patient’s ex-
cellent response.
Recently it has been demonstrated that riluzole commonly used in ALS has also some 
anti-neoplastic activities as regards to myeloma also [30], which makes this kind of thera-
py especially appropriate for comorbid cases like one described here.
In conclusion, our present ALS patient used some nutraceuticals, changed his food for 
a gluten-free diet, and obtained an excellent clinical response to improve muscle strength, 
reduce anxiety and depression symptoms, and improve his life quality. 
Ethical statement
The author declares that he followed the World Medical Association Declaration of 
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